BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verint Systems Inc. (Nasdaq – VRNT), Dayforce, Inc. (NYSE – DAY), WideOpenWest, Inc. (NYSE – WOW), Y-mAbs Therapeutics, Inc. (Nasdaq – YMAB)

BALA CYNWYD, Pa., Aug. 26, 2025 (GLOBE NEWSWIRE) — Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

Dayforce, Inc. (NYSE – DAY)

Under the terms of the Merger Agreement, Dayforce will be acquired by Thoma Bravo for $70.00 per share in cash in a deal with an enterprise value of $12.3 billion. The investigation concerns whether the Dayforce Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders. For example, the deal consideration is below the 52-week high of $82.69 for the Company’s shares.

Additional information can be found at https://www.brodskysmith.com/cases/dayforce-inc-nyse-day/.

WideOpenWest, Inc. (NYSE – WOW)

Under the terms of the agreement, WOW will be acquired by affiliated investment funds of DigitalBridge Investments, LLC and Crestview Partners (“Crestview”) for $5.20 per share in cash for each share of common stock they own. The investigation concerns whether the WOW Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/wideopenwest-inc-nyse-wow/

Verint Systems Inc. (Nasdaq – VRNT)

Under the terms of the Merger Agreement, Verint will be acquired by Thoma Bravo for $20.50 in cash for each share of Verint they own. The investigation concerns whether the Verint Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the consideration provides fair value to the Company’s shareholders. For example, the deal consideration is below the 52-week high of $34.80 for the Company’s shares.

Additional information can be found at https://www.brodskysmith.com/cases/verint-systems-inc-nasdaq-vrnt/,

Y-mAbs Therapeutics, Inc. (Nasdaq – YMAB)

Under the terms of the agreement, Y-mAbs will be acquired by SERB Pharmaceuticals (“SERB”) for $8.60 in cash for each share of Y-mAbs they own. The transaction represents a total equity value of approximately $412 million. The investigation concerns whether the Y-mAbs Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the consideration provides fair value to the Company’s shareholders.

Additional information can be found athttps://www.brodskysmith.com/cases/y-mabs-therapeutics-inc-nasdaq-ymab/.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

Wall St Business News, Latest and Up-to-date Business Stories from Newsmakers of Tomorrow